ALK1 & ROS1 Genetic Test | Lahalak Medical Platform

Advanced genetic testing to detect mutations linked to cancer risks, helping in making precise therapeutic and preventive decisions tailored to your unique health profile and needs.

Prices starts from: 1389.26 SAR

Scientific name: ALK1 and ROS1 Genetic Analysis

The ALK1 and ROS1 Genetic Test is designed to detect mutations in the ALK1 and ROS1 genes, which are associated with an increased risk of certain types of cancer, including lung cancer. This test helps understand genetic changes that may affect disease progression and response to treatment. It is an important tool in personalized medicine, as it as...

ALK1 and ROS1 Genetic Analysis - ALK1 & ROS1 Genetic Analysis
Service type Laboratory test (Genetic)
Duration 10-15 minutes
Fasting Fasting is not required
Prices Starting from 1389.26 SAR

Included Services

  • ALK1 and ROS1 Genetic Analysis Test
  • There are no special conditions for the service other than those mentioned.
  • Personal support services from Lahalak

Medical Service Information

Purpose Test

  • Diagnosis: Identifying mutations helps in accurately diagnosing the type of cancer.
  • Treatment Guidance: Assists in selecting targeted therapies that address ALK1 and ROS1 gene mutations.
  • Predicting Treatment Response: Helps anticipate how the patient may respond to therapy based on detected mutations.
  • Assessing Hereditary Risk: Aids in evaluating the potential presence of these mutations in family members.

Recommended groups

  • Lung cancer patients: Especially those with non-small cell lung cancer (NSCLC), as ALK and ROS1 mutations guide treatment options.
  • Individuals with a family history of cancer: Those with relatives affected by certain cancers to assess hereditary risk.
  • Patients unresponsive to conventional treatment: Individuals not responding adequately to chemotherapy or radiation, where genetic mutations may indicate alternative targeted therapies.
  • People with unusual symptoms: Such as persistent cough, shortness of breath, or unexplained weight loss, particularly in high-risk age or environmental groups.
  • Candidates for targeted therapy: Patients who may benefit from therapies targeting specific genetic alterations, like ALK or ROS1 inhibitors.

Symptoms indicative

  • Persistent cough: Worsening over time or cough with blood.
  • Shortness of breath: Difficulty breathing or discomfort while breathing.
  • Unexplained weight loss: Significant weight loss without changes in diet or activity.
  • Chest pain: Continuous pain or pressure in the chest area.
  • Severe fatigue: General tiredness or weakness without clear cause.
  • Night sweats: Excessive sweating at night without explanation.

FAQs

  • What is ALK1 and ROS1 Genetic Testing? It is a test used to detect genetic mutations in the ALK1 and ROS1 genes, which are associated with certain cancers, especially lung cancer.
  • Who needs this test? It is recommended for patients diagnosed with lung cancer, particularly non-small cell lung cancer (NSCLC), and for individuals with a family history of cancer or concerning symptoms.
  • How is this test performed? A sample of blood or tumor tissue is collected and analyzed in a laboratory to detect genetic mutations.
  • How long do results take? Results usually take from a few days up to two weeks, depending on the laboratory.
  • How can test results affect treatment options? If mutations in ALK1 or ROS1 are found, targeted therapies such as ALK or ROS1 inhibitors may be recommended, potentially improving treatment effectiveness.
  • Are there any risks associated with this test? The test is generally safe, but minor risks may occur from sample collection, such as pain or bruising.

Normal Levels

  • Negative Result: Indicates no mutations detected in ALK1 or ROS1, suggesting no genetic changes linked to certain cancers in the tested sample.
  • Positive Result: Indicates the presence of mutations, which may suggest an increased risk of certain cancers, such as lung cancer, and may guide targeted treatment options.
  • Negative: Suggests the patient is not at increased risk due to these specific mutations.
  • Positive: May indicate targeted therapy options and inform treatment planning.

Conditions & Notices

  • The terms and conditions announced on the "Lahalak" medical platform apply.
  • There are no special conditions for the service other than those mentioned.

Medical services you might also like